Media Releases
UPDATE: Important Information regarding Di-gesic and Doloxene.
Australian News, Media Release
UPDATE: We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.
South China Morning Post Article
Australian News, New Zealand News, Media Release
In a span of 11 years, Aspen Pharmacare Australia has become one of Australia's leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.
Business Review Australia Article
Australian News, New Zealand News, Media Release
Aspen Pharmacare Australia Expanding Global Business - from recent acquisition to expansion plans in Asia, Aspen Pharmacare Australia is ready to increase sales and markets.
Aspen Acquires Sigma's Pharmaceutical Business For AU$900 Million
Australian News, New Zealand News, Media Release
Aspen, South Africa's leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Aspen make a bid for Sigma
Australian News, Media Release
Aspen shareholders are advised that Aspen has submitted an indicative non-binding proposal to acquire, either directly or through a wholly-owned subsidiary, Sigma Pharmaceuticals Limited.
Diversity and Flexibility eNews
Australian News, New Zealand News, Media Release
Aspen's high level of flexibility has shown demonstrable business outcomes in addition to the attraction/retention of diverse talent, including consistently meeting sales objectives and extremely high value customer relationships.
Aspen take on Tritace and Cardizem
Australian News, Media Release
Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem.
